Enlivex Therapeutics Ltd.
Tel Aviv Stock Exchange ENLV.TA
Enlivex Therapeutics Ltd. Debt to Equity Ratio for the year ending December 31, 2023
Enlivex Therapeutics Ltd. Debt to Equity Ratio is NA for the year ending December 31, 2023. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
-
Enlivex Therapeutics Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.01.
-
Enlivex Therapeutics Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.01.
Key data
| Date | Debt to Equity Ratio | Debt to Income Ratio | Debt to Tangible Net Worth Ratio | Dividend Coverage Ratio |
|---|
Market news
Loading...
Don’t Miss A Beat
Tel Aviv Stock Exchange: ENLV.TA
| CEO | Dr. Oren Hershkovitz Ph.D. |
| IPO Date | July 22, 2019 |
| Location | Israel |
| Headquarters | 14 Einstein Street |
| Employees | 77 |
| Sector | Healthcare |
| Industries | |
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Key trends
Past 5 years
StockViz Staff
February 7, 2025
Any question? Send us an email